^
    Back
    Association details:
    Biomarker:BRCA2 mutation
    Cancer:Triple Negative Breast Cancer
    Drug:Actemra IV (tocilizumab) (IL-6R antagonist)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    SABCS 2023
    Title:

    Unprecedented responses to neoadjuvant sequential administration of Tocilizumab followed by cisplatin/docetaxel for locally advanced triple negative breast cancer patients

    Published date:
    12/02/2023
    Excerpt:
    Eligible patients received Tocilizumab on day 1 followed by cisplatin/docetaxel...The overall pCR and (RCB class 0+1) were 66% and 69%, respectively. Interestingly, pCR reached 81% in axilla, and 100% in patients with tumors bearing BRCA1/2 mutations.
    Secondary therapy:
    docetaxel; cisplatin